| scholarly article | Q13442814 |
| P50 | author | Gad Getz | Q32646381 |
| P2093 | author name string | Kui Chen | |
| Xiaobei Zhao | |||
| Michael C Wu | |||
| Michael S Lawrence | |||
| Derek Y Chiang | |||
| Scott Powers | |||
| Maha Guindi | |||
| Joel S Parker | |||
| Jinyu Li | |||
| Anand Ghanekar | |||
| Sean P Cleary | |||
| Gleb L Savich | |||
| Hyeja Kim | |||
| Sandra Fischer | |||
| Sara R Selitsky | |||
| Ting-Xu Tan | |||
| William R Jeck | |||
| P2860 | cites work | Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma | Q39290981 |
| Physical and functional interaction of sequestosome 1 with Keap1 regulates the Keap1-Nrf2 cell defense pathway | Q39717064 | ||
| Chromosome alterations in human hepatocellular carcinomas correlate with aetiology and histological grade--results of an explorative CGH meta-analysis | Q41886998 | ||
| Mixed lineage leukaemia-4 regulates cell-cycle progression and cell viability and its depletion suppresses growth of xenografted tumour in vivo | Q42234071 | ||
| Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma | Q44395085 | ||
| Array-based comparative genomic hybridization reveals recurrent chromosomal aberrations and Jab1 as a potential target for 8q gain in hepatocellular carcinoma. | Q46099165 | ||
| Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. | Q53168966 | ||
| COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer | Q24608391 | ||
| Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma | Q24609544 | ||
| Initial genome sequencing and analysis of multiple myeloma | Q24629117 | ||
| Somatic mutations affect key pathways in lung adenocarcinoma | Q24648102 | ||
| Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method | Q25938999 | ||
| Fast gapped-read alignment with Bowtie 2 | Q27860699 | ||
| The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data | Q27860742 | ||
| Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma | Q27860881 | ||
| Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators | Q28267500 | ||
| ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data | Q29547161 | ||
| A framework for variation discovery and genotyping using next-generation DNA sequencing data | Q29547262 | ||
| High-resolution characterization of a hepatocellular carcinoma genome | Q31005512 | ||
| Rapid growth of a hepatocellular carcinoma and the driving mutations revealed by cell-population genetic analysis of whole-genome data | Q33951424 | ||
| Cancer gene discovery in hepatocellular carcinoma | Q34002120 | ||
| Sequence analysis of mutations and translocations across breast cancer subtypes | Q34032470 | ||
| Gene expression in fixed tissues and outcome in hepatocellular carcinoma. | Q34235518 | ||
| genenames.org: the HGNC resources in 2011. | Q34456662 | ||
| Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy | Q34467880 | ||
| Association of TP53 mutations with stem cell-like gene expression and survival of patients with hepatocellular carcinoma. | Q34672668 | ||
| A tumor suppressive coactivator complex of p53 containing ASC-2 and histone H3-lysine-4 methyltransferase MLL3 or its paralogue MLL4 | Q34980453 | ||
| Targeted therapies for hepatocellular carcinoma. | Q36928888 | ||
| Focal gains of VEGFA and molecular classification of hepatocellular carcinoma | Q36984575 | ||
| Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma | Q37284612 | ||
| Nitric oxide activation of Keap1/Nrf2 signaling in human colon carcinoma cells | Q37321181 | ||
| Chromosome 1q21 amplification and oncogenes in hepatocellular carcinoma. | Q37777019 | ||
| Molecular mechanisms of the Keap1–Nrf2 pathway in stress response and cancer evolution | Q37830775 | ||
| Strategies for hepatocellular carcinoma therapy and diagnostics: lessons learned from high throughput and profiling approaches. | Q37857056 | ||
| Genetics of hepatobiliary carcinogenesis | Q37871482 | ||
| Molecularly targeted therapy for advanced hepatocellular carcinoma in 2012: current status and future perspectives | Q38030783 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatocellular carcinoma | Q1148337 |
| P304 | page(s) | 1693-1702 | |
| P577 | publication date | 2013-09-24 | |
| P1433 | published in | Hepatology | Q15724398 |
| P1476 | title | Identification of driver genes in hepatocellular carcinoma by exome sequencing | |
| P478 | volume | 58 |
| Q39809867 | 9H-purine scaffold reveals induced-fit pocket plasticity of the BRD9 bromodomain |
| Q28553513 | A Hybrid Chalcone Combining the Trimethoxyphenyl and Isatinyl Groups Targets Multiple Oncogenic Proteins and Pathways in Hepatocellular Carcinoma Cells |
| Q42064611 | A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma |
| Q90862936 | A Survey of Molecular Heterogeneity in Hepatocellular Carcinoma |
| Q36935210 | A genomic case study of mixed fibrolamellar hepatocellular carcinoma |
| Q36134242 | Accumulation of Deleterious Passenger Mutations Is Associated with the Progression of Hepatocellular Carcinoma |
| Q39062813 | Action and function of Wnt/β-catenin signaling in the progression from chronic hepatitis C to hepatocellular carcinoma |
| Q90961665 | Advancements in the Development of non-BET Bromodomain Chemical Probes |
| Q61451065 | Advances in genomic hepatocellular carcinoma research |
| Q64272351 | Application of next-generation sequencing technology to precision medicine in cancer: joint consensus of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology |
| Q64227878 | Application of plasma circulating cell-free DNA detection to the molecular diagnosis of hepatocellular carcinoma |
| Q38788315 | Biological function and histone recognition of family IV bromodomain-containing proteins |
| Q33765935 | CRISPR/Cas9-mediated p53 and Pten dual mutation accelerates hepatocarcinogenesis in adult hepatitis B virus transgenic mice |
| Q47802066 | Camptothecin suppresses NRF2-ARE activity and sensitises hepatocellular carcinoma cells to anticancer drugs |
| Q59806022 | Cancer Metabolism as a Mechanism of Treatment Resistance and Potential Therapeutic Target in Hepatocellular Carcinoma |
| Q47128083 | Chemical probes and inhibitors of bromodomains outside the BET family |
| Q52597449 | Circulating Cell-Free DNA in Hepatocellular Carcinoma: Current Insights and Outlook. |
| Q92068298 | Circulating tumor DNA correlates with microvascular invasion and predicts tumor recurrence of hepatocellular carcinoma |
| Q88654160 | Circulating-free tumour DNA and the promise of disease phenotyping in hepatocellular carcinoma |
| Q38906201 | Clinical Outcomes of TP53 Mutations in Cancers |
| Q37373034 | Clinical implication of Keap1 and phosphorylated Nrf2 expression in hepatocellular carcinoma |
| Q37718221 | Clinical outcomes based on multigene profiling in metastatic breast cancer patients |
| Q59131869 | Clinical significance of APOB inactivation in hepatocellular carcinoma |
| Q58699543 | Comprehensive assessment for miRNA polymorphisms in hepatocellular cancer risk: a systematic review and meta-analysis |
| Q42107172 | Comprehensive characterization of hepatitis B virus-associated multifocal hepatocellular carcinoma using a multi-omics strategy |
| Q38329400 | Critical roles of non-histone protein lysine methylation in human tumorigenesis |
| Q64959827 | Current issues on genomic heterogeneity in hepatocellular carcinoma and its implication in clinical practice. |
| Q89767561 | DNA and RNA sequencing identified a novel oncogene VPS35 in liver hepatocellular carcinoma |
| Q35781255 | DNA markers in molecular diagnostics for hepatocellular carcinoma |
| Q37290515 | Detecting Circulating Tumor DNA in Hepatocellular Carcinoma Patients Using Droplet Digital PCR Is Feasible and Reflects Intratumoral Heterogeneity |
| Q92619638 | Diffuse Adenomatosis and Hepatocellular Carcinoma Treated with Liver Transplantation in an Adolescent Female with Kabuki Syndrome with a Novel KMT2D Gene Mutation |
| Q49589002 | Distinction of intrahepatic metastasis from multicentric carcinogenesis in multifocal hepatocellular carcinoma using molecular alterations. |
| Q47554590 | Diverse modes of clonal evolution in HBV-related hepatocellular carcinoma revealed by single-cell genome sequencing. |
| Q60950078 | Dynamics of Axl Receptor Shedding in Hepatocellular Carcinoma and Its Implication for Theranostics |
| Q47108372 | Dysregulation of NRF2 in Cancer: from Molecular Mechanisms to Therapeutic Opportunities. |
| Q60920505 | Dysregulation of Nrf2 in Hepatocellular Carcinoma: Role in Cancer Progression and Chemoresistance |
| Q28086796 | Dysregulation of ubiquitin ligases in cancer |
| Q38997020 | Emergence of the Noncoding Cancer Genome: A Target of Genetic and Epigenetic Alterations |
| Q34619389 | Epigenetic signatures of alcohol abuse and hepatitis infection during human hepatocarcinogenesis. |
| Q26849263 | Epigenetics in liver disease |
| Q28079271 | Epigenetics in liver disease: from biology to therapeutics |
| Q36319724 | Epigenomic annotation of noncoding mutations identifies mutated pathways in primary liver cancer |
| Q64900609 | Establishment and genomic characterization of gingivobuccal carcinoma cell lines with smokeless tobacco associated genetic alterations and oncogenic PIK3CA mutation. |
| Q38214535 | Examining the impact of gene variants on histone lysine methylation |
| Q38182833 | Exploration of liver cancer genomes |
| Q37631655 | From Clinical Standards to Translating Next-Generation Sequencing Research into Patient Care Improvement for Hepatobiliary and Pancreatic Cancers |
| Q38614249 | Functional and genetic deconstruction of the cellular origin in liver cancer. |
| Q39067631 | Functions of bromodomain-containing proteins and their roles in homeostasis and cancer. |
| Q36863127 | Gankyrin has an antioxidative role through the feedback regulation of Nrf2 in hepatocellular carcinoma. |
| Q28073241 | Genetic alterations in hepatocellular carcinoma: An update |
| Q64238165 | Genome-wide profiling of Epstein-Barr virus integration by targeted sequencing in Epstein-Barr virus associated malignancies |
| Q49884832 | Genomic Analysis Revealed New Oncogenic Signatures in TP53-Mutant Hepatocellular Carcinoma. |
| Q58612842 | Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy |
| Q42220401 | Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification |
| Q47132620 | Genomic sequencing identifies a few mutations driving the independent origin of primary liver tumors in a chronic hepatitis murine model. |
| Q39404128 | Hepatocellular Malignant Neoplasm-NOS: A Clinicopathologic Study of 11 Cases from a Single Institution. |
| Q85238211 | Hepatocellular carcinoma |
| Q41682711 | High-throughput flow cytometry screening of human hepatocellular carcinoma reveals CD146 to be a novel marker of tumor-initiating cells |
| Q56976434 | Host and Viral Genetic Variation in HBV-Related Hepatocellular Carcinoma |
| Q36236839 | How do persistent infections with hepatitis C virus cause liver cancer? |
| Q34177518 | Identification and analysis of driver missense mutations using rotation forest with feature selection. |
| Q92316251 | Immunotherapy in Hepatocellular Carcinoma: Is There a Light at the End of the Tunnel? |
| Q90697982 | Implications of driver genes associated with a high tumor mutation burden identified using next-generation sequencing on immunotherapy in hepatocellular carcinoma |
| Q90270048 | Inflammatory Mechanisms of HCC Development |
| Q42248935 | KEAP the balance between life and death |
| Q99562760 | Ligation-Mediated Polymerase Chain Reaction Detection of 8-Oxo-7,8-Dihydro-2'-Deoxyguanosine and 5-Hydroxycytosine at the Codon 176 of the p53 Gene of Hepatitis C-Associated Hepatocellular Carcinoma Patients |
| Q38176242 | Liver cancer in 2013: Mutational landscape of HCC--the end of the beginning. |
| Q35913384 | Liver cancer oncogenomics: opportunities and dilemmas for clinical applications |
| Q46847748 | Local hypothyroidism favors the progression of preneoplastic lesions to hepatocellular carcinoma in rats |
| Q38686790 | Locoregional and systemic therapy for hepatocellular carcinoma |
| Q47393672 | Long Noncoding RNAs as a Key Player in Hepatocellular Carcinoma |
| Q56951623 | Machine-assisted synthesis of modulators of the histone reader BRD9 using flow methods of chemistry and frontal affinity chromatography |
| Q64977889 | Mechanisms of hepatocarcinogenesis in chronic hepatitis C. |
| Q38770560 | Metallothionein-1 as a biomarker of altered redox metabolism in hepatocellular carcinoma cells exposed to sorafenib. |
| Q34675280 | MicroRNAs in liver cancer: a model for investigating pathogenesis and novel therapeutic approaches. |
| Q41544729 | Molecular Pathogenesis of Hepatocellular Carcinoma. |
| Q26745338 | Molecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advances |
| Q26766689 | Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis? |
| Q26998606 | Multidisciplinary perspective of hepatocellular carcinoma: A Pacific Northwest experience |
| Q91637401 | Multimodal Meta-Analysis of 1,494 Hepatocellular Carcinoma Samples Reveals Significant Impact of Consensus Driver Genes on Phenotypes |
| Q54300991 | Mutational landscape of intrahepatic cholangiocarcinoma. |
| Q33618512 | Mutations acquired by hepatocellular carcinoma recurrence give rise to an aggressive phenotype |
| Q87416815 | New advances in precision medicine for hepatocellular carcinoma recurrence prediction and treatment |
| Q54170203 | Nrf2, but not β-catenin, mutation represents an early event in rat hepatocarcinogenesis. |
| Q92859614 | Phenotype-Based Screens with Conformation-Specific Inhibitors Reveal p38 Gamma and Delta as Targets for HCC Polypharmacology |
| Q64056540 | Potential Applications of NRF2 Inhibitors in Cancer Therapy |
| Q41547474 | Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy |
| Q47550861 | Primary Liver Cancers, Part 2: Progression Pathways and Carcinogenesis. |
| Q34734133 | Profiling of exome mutations associated with progression of HBV-related hepatocellular carcinoma. |
| Q58101915 | Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next Generation Sequencing for Matching Patients to Targeted and Immune Therapies |
| Q35147588 | Reciprocal interaction of Wnt and RXR-α pathways in hepatocyte development and hepatocellular carcinoma |
| Q33820159 | Recurrent activating mutation in PRKACA in cortisol-producing adrenal tumors |
| Q93016086 | Regulation of expression of drug-metabolizing enzymes by oncogenic signaling pathways in liver tumors: a review |
| Q56972496 | Roles of p53 in extrinsic factor-induced liver carcinogenesis |
| Q35919725 | Significance of genetic variants in DLC1 and their association with hepatocellular carcinoma |
| Q91657327 | Somatic mutation signatures in primary liver tumors of workers exposed to ionizing radiation |
| Q90911608 | Somatic mutations and clonal dynamics in healthy and cirrhotic human liver |
| Q37031712 | Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives |
| Q26746255 | T3/TRs axis in hepatocellular carcinoma: new concepts for an old pair |
| Q37722129 | TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma |
| Q92740295 | TRIM25 promotes the cell survival and growth of hepatocellular carcinoma through targeting Keap1-Nrf2 pathway |
| Q37408915 | Target genes discovery through copy number alteration analysis in human hepatocellular carcinoma |
| Q36356419 | Targeted DNA and RNA sequencing of fine-needle biopsy FFPE specimens in patients with unresectable hepatocellular carcinoma treated with sorafenib |
| Q92504694 | Targeted genomic profiling identifies frequent deleterious mutations in FAT4 and TP53 genes in HBV-associated hepatocellular carcinoma |
| Q38923977 | Targeting multiple oncogenic pathways for the treatment of hepatocellular carcinoma |
| Q26830194 | Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends |
| Q53232555 | Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. |
| Q57067866 | Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers? |
| Q37336099 | The MLL3/MLL4 branches of the COMPASS family function as major histone H3K4 monomethylases at enhancers |
| Q89454724 | The critical role of glucose deprivation in epithelial-mesenchymal transition in hepatocellular carcinoma under hypoxia |
| Q98891422 | The genomic landscape of Mongolian hepatocellular carcinoma |
| Q34458870 | The genomic landscape of fibrolamellar hepatocellular carcinoma: whole genome sequencing of ten patients. |
| Q37720697 | The importance of a multidisciplinary approach to hepatocellular carcinoma |
| Q26777478 | The mutational landscape of hepatocellular carcinoma |
| Q41191439 | Therapeutic strategies for hepatocellular carcinoma: new advances and challenges |
| Q99352179 | Therapy of Primary Liver Cancer |
| Q40493822 | Transcriptome sequencing identified hub genes for hepatocellular carcinoma by weighted-gene co-expression analysis. |
| Q46609299 | Ubiquitin ligases in oncogenic transformation and cancer therapy |
| Q40046596 | Viral hepatitis and liver cancer. |
| Q98946922 | Whole-exome mutational landscape of metastasis in patient-derived hepatocellular carcinoma cells |
| Q35169245 | p53 requires the stress sensor USF1 to direct appropriate cell fate decision. |
| Q28392820 | p62 links autophagy and Nrf2 signaling |
| Q38893853 | p62/SQSTM1-Dr. Jekyll and Mr. Hyde that prevents oxidative stress but promotes liver cancer |
Search more.